Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment Optimization Trial in Chronic Myeloid Leukemia (CML)
NCT00055874Phase 3Completed
- Sponsor
- Heidelberg University
- Start
- Jun 2002
- Primary completion
- Mar 2012
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of imatinib in chronic myeloid leukemia (CML) (4 arms), sponsored by Heidelberg University. Primary endpoints: Overall Survival, Risk group-dependent survival and 4 more. Started Jun 2002; status: completed.
02
Drugs
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT00055874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00055874.